Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Schrödinger, Inc. (NASDAQ:SDGR) has been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $32.90.

Separately, BMO Capital Markets increased their price objective on shares of Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th.

Insider Activity at Schrödinger

In other Schrödinger news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total transaction of $27,221.18. Following the transaction, the insider now directly owns 13,469 shares of the company’s stock, valued at approximately $239,478.82. This trade represents a 10.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in Schrödinger by 87.5% during the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after purchasing an additional 1,305 shares during the last quarter. JPMorgan Chase & Co. grew its position in Schrödinger by 3.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 122,702 shares of the company’s stock worth $2,276,000 after purchasing an additional 4,403 shares during the last quarter. Geode Capital Management LLC grew its position in Schrödinger by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,319,205 shares of the company’s stock worth $24,476,000 after purchasing an additional 24,114 shares during the last quarter. Barclays PLC grew its position in Schrödinger by 421.6% during the 3rd quarter. Barclays PLC now owns 107,554 shares of the company’s stock worth $1,995,000 after purchasing an additional 86,933 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Schrödinger by 1.8% in the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company’s stock worth $39,987,000 after acquiring an additional 38,972 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Schrödinger Stock Down 5.1 %

Schrödinger stock opened at $19.29 on Friday. The firm has a market cap of $1.41 billion, a PE ratio of -8.24 and a beta of 1.59. Schrödinger has a 52-week low of $16.67 and a 52-week high of $33.63. The company’s 50 day moving average is $20.40 and its two-hundred day moving average is $20.00.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm had revenue of $35.30 million during the quarter, compared to analysts’ expectations of $41.25 million. During the same period in the prior year, the company posted ($0.86) earnings per share. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. On average, equities research analysts anticipate that Schrödinger will post -2.29 earnings per share for the current fiscal year.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.